Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Fig. 5

Long-term dynamic changes in UA and the percentage of hyperuricemia (UA ˃ 420 µmol/L) over 144 weeks after initial ART with TDF plus 3TC plus EFV in treatment-naive patients with HIV (n = 61). A UA level. B the percentage of hyperuricemia. ART, active antiretroviral therapy. TDF, Tenofovir. 3TC, Lamivudine. EFV, Efavirenz. UA, uric acid. ANOVA was used to compare UA levels from baseline to 144 weeks, and a paired t-test was used to compare UA levels between baseline and some follow-up time points. The Kruskal-Wallis H(K) test for K independent samples was used to compare the percentage of hyperuricemia from baseline to 144 weeks. The Mann-Whitney test for two independent samples was used to compare the percentage of hyperuricemia between baseline and follow-up time points. Comparison between different time points and compared with baseline, all P > 0.05

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us